Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 278

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center Experience

Open access
Faris, Jason E., Blaszkowsky, Lawrence S., McDermott, Shaunagh, Guimaraes, Alexander R., Szymonifka, Jackie, Huynh, Mai Anh, Ferrone, Cristina R., Wargo, Jennifer A., Allen, Jill N., Dias, Lauren E., Kwak, Eunice L., Lillemoe, Keith D., Thayer, Sarah P., Murphy, Janet E., Zhu, Andrew X., Sahani, Dushyant V., Wo, Jennifer Y., Clark, Jeffrey W., Fernandez-del Castillo, Carlos, Ryan, David P., Hong, Theodore S.·2013·The Oncologist

Abstract

The objective of our retrospective institutional experience is to report the overall response rate, R0 resection rate, progression-free survival, and safety/toxicity of neoadjuvant FOLFIRINOX (5-fluorouracil [5-FU], oxaliplatin, irinotecan, and leucovorin) and chemoradiation in patients with locally advanced pancreatic cancer (LAPC). Patients with LAPC treated with FOLFIRINOX were identified via the Massachusetts General Hospital Cancer Center pharmacy database. Demographic information, clinical characteristics, and safety/tolerability data were compiled. Formal radiographic review was performed to determine overall response rates (ORRs). Twenty-two patients with LAPC began treatment with FOLFIRINOX between July 2010 and February 2012. The ORR was 27.3%, and the median progression-free survival was 11.7 months. Five of 22 patients were able to undergo R0 resections following neoadjuvant FOLFIRINOX and chemoradiation. Three of the five patients have experienced distant recurrence within 5 months. Thirty-two percent of patients required at least one emergency department visit or hospitalization while being treated with FOLFIRINOX. FOLFIRINOX possesses substantial activity in patients with LAPC. The use of FOLFIRINOX was associated with conversion to resectability in >20% of patients. However, the recurrences following R0 resection in three of five patients and the toxicities observed with the use of this regimen raise important questions about how to best treat patients with LAPC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1634/theoncologist.2012-0435

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 278

Metadata

Authors
Faris, J. E., Blaszkowsky, L. S., McDermott, S., Guimaraes, A. R., Szymonifka, J., Huynh, M. A., Ferrone, C. R., Wargo, J. A., Allen, J. N., Dias, L. E., Kwak, E. L., Lillemoe, K. D., Thayer, S. P., Murphy, J. E., Zhu, A. X., Sahani, D. V., Wo, J. Y., Clark, J. W., Fernandez-del Castillo, C., Ryan, D. P., & Hong, T. S.
Venue
The Oncologist
Published
2013-05-01
Volume
18
Issue
5
Pages
543-548
ISSN
  • 1083-7159 (ISSN-L)
  • 1549-490X
OpenAlex
W2121608920
Cited by
278
References
15
FWCI
15.18
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center Experience. https://app.cochat.ai/papers/10.1634/theoncologist.2012-0435
The paper
Faris, J. E., Blaszkowsky, L. S., McDermott, S., Guimaraes, A. R., Szymonifka, J., Huynh, M. A., Ferrone, C. R., Wargo, J. A., Allen, J. N., Dias, L. E., Kwak, E. L., Lillemoe, K. D., Thayer, S. P., Murphy, J. E., Zhu, A. X., Sahani, D. V., Wo, J. Y., Clark, J. W., Fernandez-del Castillo, C., . . . Hong, T. S. (2013). FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center Experience. The Oncologist. https://doi.org/10.1634/theoncologist.2012-0435

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.